Search results
Results from the WOW.Com Content Network
Cobimetinib or XL518, approved by US FDA in Nov 2015 for use in combination with vemurafenib (Zelboraf(R)), for treatment of advanced melanoma with a BRAF V600E or V600K mutation. Selumetinib , had a phase 2 clinical trial for non-small cell lung cancer (NSCLC) which demonstrated an improvement in PFS, [ 5 ] and is now in phase III development ...
Tigilanol tiglate (USAN; [1]), sold under the brand name Stelfonta is a medication used to treat dogs with non-metastatic, skin-based mast cell tumors (MCTs). The FDA is also approving Stelfonta to treat non-metastatic MCTs located under the dog's skin (subcutaneous), in particular areas of a dog's leg. [2]
Toceranib (INN [2]), sold under the brand name Palladia, is a receptor tyrosine kinase inhibitor that is used in the treatment of canine mast cell tumor also called mastocytoma. [3] It is the first medication developed specifically for the treatment of cancer in dogs. [4] [5] It is used as its phosphate salt, toceranib phosphate.
Related: First FDA-Approved Anti-Aging Medication for Dogs Might Be on Its Way. Many pet owners have found that their dogs have had severe reactions to the medication. The reactions have ranged ...
The drug is FDA-approved for prevention of heartworm in dogs and cats, [4] although it is less potent against heartworms than ivermectin. [citation needed] The substance is often combined with other parasiticides to achieve a broader spectrum of action. Such products include: [citation needed] Milbemax and Interceptor Plus (with praziquantel)
More than 3,600 cases of debilitating dog health problems caused by the medication were reported between January 2023 and March 2024, the FDA said in the cautionary letter, published Monday.
FDA Approves APOQUEL ® (oclacitinib tablet) to Control Itch and Inflammation in Allergic Dogs Zoetis Offers a Targeted New Approach to Rapidly and Safely Stop the Cycle of Itch and Inflammation ...
Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. [5] Inappropriate activation of the pathway has been shown to occur in many cancers. [ 5 ] In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K ...